Table 2 Pulsed-field types, antimicrobial resistance, and resistance and virulence genes, of methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) isolates from personnel screened in the US and Afghanistan
| Â | MRSA | MSSA | ||||
|---|---|---|---|---|---|---|
US | Afghan | Total | Â US | Â Afghan | Â Total | |
Pulsed-field types a | 4 | 4 | 8 | Â 42 | 35 | 77 |
 Community-associated isolates n(%) | 3(75) | 1(25) | 4(50) |  4(10) |  3(9) |  7 (9) |
  USA 300 | 3(75)c | 1(25) | 4(50)d |  2(5)c |  2(6) |  4(5)d |
  USA 400 | 0 | 0 | 0 |  2(5) |  1(3) |  3(4) |
 Healthcare-associated isolates n(%) | 1(25) | 3(75) | 4(50) | 38(90) | 32(91) | 70(91) |
  USA 200 | 0 | 0 | 0 |  9(21) |  6(17) | 15(20) |
  USA 500 | 0 | 0 | 0 |  0 |  5(14) |  5(6) |
  USA 600 | 0 | 0 | 0 |  2(5) |  1(3) |  3(4) |
  USA 700 | 1(25) | 0 | 1(12) |  0 |  2(6) |  2(3) |
  USA 800 | 0 | 1(25) | 1(12) |  7(16) |  7(20) | 14(18) |
  USA 900 | 0 | 0 | 0 |  5(12) |  2(6) |  7(9) |
  USA 1000 | 0 | 2(50) | 2(12) |  2(5) |  5(14) |  7(9) |
 Other (%) | 0 | 0 | 0 | 13(31) |  4(11) | 17(22) |
Antimicrobial susceptibility and presence of antimicrobial resistance gene n(%) b | 4 | 4 | 8 | 47 | 35 | 82 |
 Ampicillin | 0 | 0 | 0 |  0 |  0 |  0 |
 Ampicillin-sulbactam | 0 | 0 | 0e | 47(100) | 35(100) | 82(100)e |
 Penicillin G | 0 | 0 | 0 | 10(21) |  6(17) | 16(19) |
  blaZ | 4(100) | 4(100) | 8(100) | 36(77) | 29(83) | 65(79) |
 Clindamycin | 3(75) | 4(100) | 7 (87) | 39(83) | 29(83) | 68(83) |
  ermA | 0 | 0 | 0 |  8(17) |  4(11) | 12(15) |
  ermB and ermT | 0 | 0 | 0 |  0 |  0 |  0 |
  ermC | 1(25) | 0(0) | 1 (12) |  0 |  0 |  0 |
 Erythromycin | 0 | 1(25) | 1 (12)f | 34(72) | 22(63) | 56(68)f |
  msrA | 3(75)g | 3(75) | 6(75)h | 2(4)g |  8(23) | 10(12)h |
  ermA | 1(25) | 0 | 1(12) | 8(17) |  4(11) | 12(15) |
 Levofloxacin | 2(50)i | 4(100) | 6(75)j | 46(98)i | 35(100) | 81(99)j |
 Moxifloxacin | 2(50)k | 4(100) | 6(75)l | 46(98)k | 35(100) | 81(99)l |
 Rifampin | 4(100) | 4(100) | 8(100) | 47(100) | 35(100) | 82(100) |
 Doxycycline | 4(100) | 4(100) | 8(100) | 46(98) | 33(94) | 79 (98) |
 Minocycline | 4(100) | 4(100) | 8(100) | 47(100) | 33(94) | 80(98) |
 Tetracycline | 4(100) | 4(100) | 8(100) | 46(98) | 25(71) | 71(87) |
  tetK | 0 | 0 | 0 |  0m |  6(17)m |  6(7) |
  tetL and tetO | 0 | 0 | 0 |  0 |  0 |  0 |
  tetM | 0 | 0 | 0 |  1(2)n |  2(6)n |  3(4) |
 Trimethoprim - sulfamethoxazole | 4(100) | 4(100) | 8(100) | 45(96) | 35(100) | 80(98) |
  dfrA and dfrK | 0 | 0 | 0 |  0 |  0 |  0 |
Other resistance and virulence markers (%) b | 4 | 4 | 8 | 47 | 35 | 82 |
 mecA | 4(100) | 4(100) | 8(100) |  0 |  0 |  0 |
 SCCmec | 4(100) | 4(100) | 8(100) |  0 |  0 |  0 |
 PVL | 1(25) | 1(25) | 2(25)o |  1(2) |  1(3) |  2(2)o |
 ACME | 2(50)p | 1(25) | 3(37)q |  0p |  0 |  0q |
 Agr I | 4(100) | 1(25) | 5(62) | 15(32) | 11(31) | 26(32) |
 Agr II | 0 | 1(25) | 1(12) | 15(32) | 12(34) | 27(33) |
 Agr III | 0 | 0 | 0 |  0r | 11(31)r | 11(13) |